EBODAC - Communication strategy and tools for optimizing the impact of Ebola vaccination deployment - H2020
The EBODAC consortium consists of 4 partners: Janssen (EFPIA), London School of Hygiene and Tropical Medicine (LSHTM), World Vision of Ireland and Grameen Foundation . These partners have experience and expertise in:
• (Ebola) vaccine development and vaccine acceptance; m-health deployments for disease management in resource limited settings (Janssen).
• Vaccine acceptance; risk management in health programs (LSHTM).
• Mobile health deployments for emergency assistance; communication and training delivery in emergency settings (World Vision).
• Mobile health software development and deployment in resource limited settings (Grameen).
As such, the EBODAC consortium is well placed to tackle the challenges associated with Ebola vaccine deployment, including:
• Stigma related to Ebola infections.
• Lack of understanding and distrust versus vaccines in general in the local endemic communities.
• Two step prime/booster regimen for Ebola vaccine: risk for a 'no show' for the booster shot, risk for presenting for the booster shot too early or too late; risk for a different person presenting for the booster shot vs. the prime shot.
• People may be difficult to reach for the vaccine recall; People may live at a large distance from the health center where the vaccine is delivered.
• Risk for data on vaccine coverage to be fragmented, not existing or incorrect.
The EBODAC consortium is committed to deliver:
• A communication strategy that will optimize vaccine acceptance, supported by local anthropology research data.
• A platform, based on mobile phone technology, for Ebola vaccine recalls, information/education on Ebola and vaccines in general; and tracking of vaccination coverage.
• An identification tool to allow to match the identity of individuals in the prime and boost vaccine regimens.
• A training program in the local setting, and a helpdesk function, to support the m-health platform, and the communication strategy deployment.
The project currently is designed to take 3 years, but will have to synchronize with the timelines and outcome of the IMI2 Ebola+ Call, Topic 1.
Document Type: Research Article
Publication date: October 15, 2018
Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.
- Subscribe to this Title
- Terms & Conditions
- Disseminating research in Impact
- Information about Impact
- Ingenta Connect is not responsible for the content or availability of external websites